The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Mark R. Middleton
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Agalimmune; Amgen; Array BioPharma; BioLineRx; Bristol-Myers Squibb; Clovis Oncology; CytomX Therapeutics; GlaxoSmithKline; Immunocore; Medicenna; Newlink Genetics; RigonTEC; Roche; Takeda
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
P. Taylor Eves
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
 
Viviana Bozon
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
 
Adam P. Boyd
Employment - Array BioPharma
Stock and Other Ownership Interests - Array BioPharma
Consulting or Advisory Role - Jaguar Health; TERUMO
Travel, Accommodations, Expenses - Array BioPharma
 
Jan H.M. Schellens
No Relationships to Disclose